EE04868B1 - Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis - Google Patents

Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis

Info

Publication number
EE04868B1
EE04868B1 EEP200100221A EEP200100221A EE04868B1 EE 04868 B1 EE04868 B1 EE 04868B1 EE P200100221 A EEP200100221 A EE P200100221A EE P200100221 A EEP200100221 A EE P200100221A EE 04868 B1 EE04868 B1 EE 04868B1
Authority
EE
Estonia
Prior art keywords
aqueous
sertraline
pharmaceutically acceptable
acceptable salt
amount
Prior art date
Application number
EEP200100221A
Other languages
English (en)
Estonian (et)
Inventor
ning selle kontsentraadi v?i selle farmatseutiliselt vastuv?etava soola kasutamine sertraliini vesilahuse valmistamiseks ti
Jane Harper Nancy
Ramchandra Ranade Gautam
Mckowan Welch Willard
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22298286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04868(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100221A publication Critical patent/EE200100221A/xx
Publication of EE04868B1 publication Critical patent/EE04868B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100221A 1998-10-13 1999-09-22 Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis EE04868B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10402498P 1998-10-13 1998-10-13
PCT/IB1999/001571 WO2000021521A2 (fr) 1998-10-13 1999-09-22 Concentre de sertraline par voie orale

Publications (2)

Publication Number Publication Date
EE200100221A EE200100221A (et) 2002-08-15
EE04868B1 true EE04868B1 (et) 2007-08-15

Family

ID=22298286

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100221A EE04868B1 (et) 1998-10-13 1999-09-22 Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis

Country Status (46)

Country Link
EP (1) EP1121107B1 (fr)
JP (1) JP3792514B2 (fr)
KR (1) KR100417200B1 (fr)
CN (1) CN1184962C (fr)
AP (1) AP2001002119A0 (fr)
AR (1) AR014082A1 (fr)
AT (1) ATE254453T1 (fr)
AU (1) AU766202B2 (fr)
BG (1) BG65085B1 (fr)
BR (1) BR9914418A (fr)
CA (1) CA2346335C (fr)
CO (1) CO5150213A1 (fr)
CZ (1) CZ20011286A3 (fr)
DE (1) DE69912978T2 (fr)
DK (1) DK1121107T3 (fr)
DZ (1) DZ2913A1 (fr)
EA (1) EA003990B1 (fr)
EE (1) EE04868B1 (fr)
EG (1) EG23818A (fr)
ES (1) ES2209490T3 (fr)
GC (1) GC0000175A (fr)
GE (1) GEP20032969B (fr)
GT (1) GT199900171A (fr)
HK (1) HK1040199B (fr)
HR (1) HRP20010263B1 (fr)
HU (1) HUP0104470A3 (fr)
ID (1) ID29845A (fr)
IS (1) IS2239B (fr)
MA (1) MA26698A1 (fr)
MY (1) MY122477A (fr)
NO (1) NO20011829L (fr)
NZ (1) NZ510756A (fr)
OA (1) OA11662A (fr)
PA (1) PA8483301A1 (fr)
PE (1) PE20001108A1 (fr)
PL (1) PL348119A1 (fr)
PT (1) PT1121107E (fr)
PY (1) PY990106A (fr)
SK (1) SK4582001A3 (fr)
TN (1) TNSN99190A1 (fr)
TR (1) TR200101090T2 (fr)
TW (1) TWI228043B (fr)
UA (1) UA72743C2 (fr)
WO (1) WO2000021521A2 (fr)
YU (1) YU26401A (fr)
ZA (1) ZA200102900B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1671628B1 (fr) 1999-09-03 2012-10-03 APBI Holdings, LLC Inhibiteurs de réabsorption de sérotonine à action rapide pour le traitement des dysfonctions sexuelles
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2004065348A1 (fr) 2003-01-23 2004-08-05 Pfizer Products Inc. Sels pharmaceutiquement acceptables de sertraline et compositions pharmaceutiques correspondantes
WO2005000786A1 (fr) * 2003-05-23 2005-01-06 Transform Pharmaceuticals, Inc. Compositions de sertraline
WO2005034910A1 (fr) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Compositions pharmaceutiques liquides de sertraline a administration orale
WO2007052152A2 (fr) * 2005-11-07 2007-05-10 Aurobindo Pharma Limited Concentré oral d'un antidépresseur
WO2008112641A2 (fr) * 2007-03-09 2008-09-18 New York University Procédés et compositions pour le traitement de la dysrythmie thalamocorticale
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
CA2143070C (fr) * 1994-02-22 2001-12-18 Pankaj Modi Formulation pharmaceutique sous forme de suspension liquide administree par voie orale, pour degagement prolonge
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
SE508372C2 (sv) * 1995-02-13 1998-09-28 Kjell Lindstroem Metod och utrustning för tillförsel eller aspiration av substanser inom gastrointestinalkanalen, avsedd för mätning av farmakokinetiska och fysikalisk-kemiska parametrar
ATE235237T1 (de) * 1995-07-17 2003-04-15 Pfizer Sertralin zur behandlung von post-myocard-infarkt-patienten
EP0980241B1 (fr) * 1997-07-01 2003-12-17 Pfizer Products Inc. Formes posologiques de sertraline, en solution et encapsulees dans de la gelatine

Also Published As

Publication number Publication date
TNSN99190A1 (fr) 2005-11-10
CA2346335A1 (fr) 2000-04-20
MA26698A1 (fr) 2004-12-20
PE20001108A1 (es) 2000-10-26
NO20011829L (no) 2001-06-05
AR014082A1 (es) 2001-01-31
CN1184962C (zh) 2005-01-19
TWI228043B (en) 2005-02-21
CO5150213A1 (es) 2002-04-29
EE200100221A (et) 2002-08-15
UA72743C2 (en) 2005-04-15
KR20010080096A (ko) 2001-08-22
KR100417200B1 (ko) 2004-02-05
JP3792514B2 (ja) 2006-07-05
TR200101090T2 (tr) 2001-12-21
ZA200102900B (en) 2002-05-29
HUP0104470A2 (en) 2002-08-28
EA003990B1 (ru) 2003-12-25
PA8483301A1 (es) 2000-09-29
PY990106A (es) 2007-11-01
PT1121107E (pt) 2004-02-27
MY122477A (en) 2006-04-29
HUP0104470A3 (en) 2003-12-29
NO20011829D0 (no) 2001-04-10
PL348119A1 (en) 2002-05-06
WO2000021521A3 (fr) 2000-07-20
GT199900171A (es) 2001-03-28
CN1323202A (zh) 2001-11-21
ID29845A (id) 2001-10-18
CZ20011286A3 (cs) 2001-09-12
DE69912978T2 (de) 2004-04-22
HK1040199A1 (en) 2002-05-31
IS2239B (is) 2007-05-15
AU766202B2 (en) 2003-10-09
EP1121107B1 (fr) 2003-11-19
WO2000021521A2 (fr) 2000-04-20
GC0000175A (en) 2006-03-29
BG65085B1 (bg) 2007-02-28
IS5906A (is) 2001-03-23
SK4582001A3 (en) 2002-02-05
EG23818A (en) 2007-09-19
HRP20010263A2 (en) 2002-06-30
EP1121107A2 (fr) 2001-08-08
GEP20032969B (en) 2003-05-27
HK1040199B (zh) 2005-05-27
DE69912978D1 (de) 2003-12-24
ATE254453T1 (de) 2003-12-15
NZ510756A (en) 2003-05-30
BG105434A (bg) 2001-12-29
AU5643699A (en) 2000-05-01
EA200100285A1 (ru) 2001-10-22
JP2002527385A (ja) 2002-08-27
ES2209490T3 (es) 2004-06-16
DK1121107T3 (da) 2004-02-23
HRP20010263B1 (en) 2005-04-30
DZ2913A1 (fr) 2004-03-01
YU26401A (sh) 2005-07-19
AP2001002119A0 (en) 2001-03-22
OA11662A (en) 2004-12-08
BR9914418A (pt) 2001-06-26
CA2346335C (fr) 2006-04-18

Similar Documents

Publication Publication Date Title
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
NO20020208L (no) Flytende sammensetninger for oral administrasjon
AU762322C (en) Novel galenic formulations of meloxicam for oral administration
EE04450B1 (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
PL333524A1 (en) Improved prolonged release pharmaceutic preparation for administration of nephadosone, oral dosage form thereof and improved nephadosone administration method
CA2377174A1 (fr) Formes galeniques orales servant a administrer une combinaison fixe de tramadol et de diclofenac
EE04997B1 (et) Loteprednooli ja antihistamiinseid aineid sisaldav farmatseutiline kompositsioon, neid aineid sisaldav ravim, meetod selle ravimi valmistamiseks ja nende ainete kombinatsiooni kasutamine
PT1210119E (pt) Composicoes farmaceuticas para administracao oral e topica
IT1302682B1 (it) Composizioni farmaceutiche orali contenenti buprenorfina
HUP0103431A3 (en) Pharmaceutical, oral compositions containing 5-ht4 agonists or antagonists as active agent
EE04868B1 (et) Farmatseutiline kompositsioon, mis sisaldab vett mittesisaldavat, vedelat kontsentraati oraalseks manustamiseks, mis sisaldab sertraliini v?i selle farmatseutiliselt vastuv?etava soola kogust ning hte v?i rohkemat vett mittesisaldavat farmatseutilis
EE04914B1 (et) Eletriptaanvesinikbromiidi monohüdraat, selle kasutamine ja protsess selle valmistamiseks ning eletriptaanvesinikbromiidi monohüdraati sisaldav farmatseutiline kompositsioon
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
HUP0200729A3 (en) Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
HUP0200605A3 (en) Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them
EE200100196A (et) a-tsüklodekstriinil põhinevad farmatseutilised kompositsioonid LH-RH analoogide peroraalseks manustamiseks
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
AR018092A1 (es) Composicion farmaceutica liquida para administracion oral
NO20003284L (no) Farmasøytisk preparat for oral administrering
DK1165081T3 (da) Fremgangsmåde til fremstilling af tolperisonholdige farmaceutiske præparater til oral indgivelse

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20080922